-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Smoky myeloma (smoldering myeloma) refers to multiple myeloma that meets the diagnostic criteria for multiple myeloma , but the disease progresses slowly and has no clinical symptoms
.
The risk of high-risk smoking myeloma developing into symptomatic multiple myeloma within 5 years is approximately 75%
Smoldering myeloma refers to multiple myeloma that meets the diagnostic criteria for multiple myeloma , but the disease progresses slowly and has no clinical symptoms.
This study aims to evaluate the effect of carfilzomib, lenalidomide and dexamethasone (KRd) combined with lenalidomide maintenance therapy as an early intervention for high-risk smoking myeloma to identify minimal residual disease (MRD) The incidence of negative complete remission (CR)
.
Research Process
Research ProcessThis is a single-arm, single-center phase 2 non-randomized controlled trial that evaluated the remission rate after KRd treatment
.
Early-stage smoking myeloma patients received 8 courses of KRd treatment, followed by 28 courses of lenalidomide maintenance treatment
Survival rate without progression to multiple myeloma
Survival rate without progression to multiple myelomaA total of 54 patients (median age 59 years, 30 men) were recruited, and the median follow-up was 31.
9 months (range 6.
7-102.
9 months)
.
The complete response rate of negative MRD was 70.
The complete response rate for MRD negative was 70.
High-risk smoking myeloma adopts new triple treatment options, such as KRd and lenalidomide maintenance treatment, which may change the natural history of smoking myeloma by significantly delaying the development of end-organ disease.
Original source:
Kazandjian D, Hill E, Dew A, et al.
Carfilzomib, Lenalidomide, and Dexamethasone the Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-Risk Smoldering Myeloma: A nonrandomized Phase 2 Controlled Trial JAMA in this message
